Écrit par ABIVAX | 12 Février 2016

Paris, France, le 11 février 2016 - ABIVAX (Euronext Paris : FR0012333284 - ABVX), société de biotechnologie leader dans le développement clinique et la commercialisation de médicaments antiviraux et de vaccins thérapeutiques pour des maladies telles que le VIH/sida et l'hépatite B chronique, annonce aujourd'hui la participation du Professeur Hartmut Ehrlich, M.D., Directeur Général...

Écrit par GBI Research | 11 Février 2016

NEW YORK (GBI Research), 10 February 2016 - The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion in 2021, at a Compound Annual Growth Rate (CAGR) of 11%, according to business intelligence provider GBI Research.

The company’s latest report* states that such impressive growth, which will occur across the eight major...

Écrit par Wiley | 11 Février 2016

New research uncovers a cascade of reactions within nerve cells that relay sensations of pain associated with inflammation. The findings, which are published in the British Journal of Pharmacology, indicate that drugs designed to curb this pathway may help relieve inflammatory pain in sufferers.

Previous studies identified that a molecule called Rac1 maintains chronic neuropathic pain...

Écrit par GlobalData | 10 Février 2016

LONDON, UK (GlobalData), 9 February 2016 - A new hand-held blood test that can be used to detect mild traumatic brain injuries, or concussions, developed by Koninklijke Philips (Philips) in partnership with Banyan Biomarkers, could enable Philips to capture a greater share of a global in vitro diagnostic test market anticipated to exceed $10 billion by 2021, says an analyst with research...